Intrinsic Value of S&P & Nasdaq Contact Us

CeriBell, Inc. CBLL NASDAQ

NASDAQ Global Select • Healthcare • Medical - Devices • US • USD

SharesGrow Score
55/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$30.00
+46.1%

CeriBell, Inc. (CBLL) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 4 Buy.

The consensus price target is $30.00, representing an upside of 46.1% from the current price $20.53.

Analysts estimate Earnings Per Share (EPS) of $-2.20 and revenue of $0.06B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-3.89 vs est $-2.20 (missed -77%). 2025: actual $-1.46 vs est $-1.51 (beat +3.1%). Analyst accuracy: 77%.

CBLL Stock — 12-Month Price Forecast

$30.00
▲ +46.13% Upside
Average Price Target
Based on 4 Wall Street analysts offering 12-month price targets for CeriBell, Inc., the price target is $30.00.
The average price target represents a +46.13% change from the last price of $20.53.

CBLL Analyst Ratings

Buy
4
Ratings
4 Buy
Based on 4 analysts giving stock ratings to CeriBell, Inc. in the past 3 months
Rating breakdown
Buy
4 100%
100%
Buy
4 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

EPS Estimates — CBLL

77%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024 Actual –$3.89 vs Est –$2.20 ▼ 43.5% off
2025 Actual –$1.46 vs Est –$1.51 ▲ 3.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.

Revenue Estimates — CBLL

99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual $0.065B vs Est $0.064B ▲ 1.8% off
2025 Actual $0.089B vs Est $0.088B ▲ 1.0% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message